NMIBC

Durvalumab in NMIBC Care

View All

Panel of medical experts discussing immunotherapy, bladder cancer, and multidisciplinary care for non-muscle invasive bladder cancer (NMIBC).

Durvalumab in NMIBC Care

06/11/2026

Real-World Integration, Immune Toxicity, and the Future of Multidisciplinary NMIBC Care

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Medical panel discussing Potomac trial results on Durvalumab and BCG therapy improving recurrence-free survival in cancer patients.

Durvalumab in NMIBC Care

06/09/2026

POTOMAC Trial Breakthrough: Durvalumab Plus BCG Shows Improved Recurrence-Free Survival

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Key oncology trial highlights Durvalumab and BCG combination improving disease-free survival, featuring experts Dr. Shilpa Gupta, Dr. Neal Shore, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Amit Patel.

Durvalumab in NMIBC Care

06/09/2026

POTOMAC Trial Breakthrough: Durvalumab Plus BCG Shows Improved Disease-Free Survival

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Panel discussion on high-risk non-muscle invasive bladder cancer (NMIBC) and BCG treatment limits featuring Dr. Shilpa Gupta, Dr. Neal Shore, Dr. Rohit Gosain, Dr. Rahul Gosain, and Dr. Amit Patel.

Durvalumab in NMIBC Care

06/08/2026

Defining High-Risk Non–Muscle-Invasive Bladder Cancer and the Limits of BCG Alone

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD

Panel of oncology experts discussing the integration of Durvalumab into non-muscle invasive bladder cancer (NMIBC) treatment strategies.

Durvalumab in NMIBC Care

06/04/2026

Clinical Insights: Integrating Durvalumab Into Non–Muscle-Invasive Bladder Cancer Care

Shilpa Gupta, MDAmit Patel, MDNeal Shore, MD, FACSRahul Gosain, MD, MBARohit Gosain, MD